London, November 16 (ots/PRNewswire) - - For Non-US Media Only - PROactive Study Also Shows a 37 Percent Reduction in Acute Coronary Syndrome With ACTOS New results from secondary analyses of the landmark PROactive Study found that ACTOS(R) (pioglitazone) significantly reduced the occurrence of fatal ...
London (ots/PRNewswire) - - Takeda's ACTOS(R) (pioglitazone HCl) on Top of Standard Treatment Demonstrates Significant Cardiovascular Benefits A study published in The Lancet today shows that Takeda's ACTOS(R) (pioglitazone HCl), an oral glucose lowering medication, significantly reduces the combined risk ...
Athens, Greece (ots/PRNewswire) - Landmark data from the PROactive Study, presented today at the 41st meeting of the European Association for the Study of Diabetes (EASD) demonstrated that ACTOS(R) (pioglitazone HCl) significantly reduces the combined risk of heart attacks, strokes and death by 16% in high risk ...